Little Green Pharma (LGP) has appointed as a primary medicinal cannabis oil manufacturer for a national French medicinal cannabis trial in partnership with Intsel Chimos, a leading French pharmaceutical distributor.
The trial is intended to test the efficacy, safety, and quality of medicinal cannabis medicines for the French public and plans to recruit up to 3,000 patients over its duration.
LGP’s partner in the trial, Intsel Chimos, is a French pharmaceutical company and recognised hospital partner, specialising in the importation and distribution of medicines (including narcotics) to French hospitals and dispensaries.
Under the partnership, LGP will manufacture and supply its medicines into France while Intsel Chimos will undertake batch-release, distribution, medical information, and pharmacovigilance obligations.
If successful, the trial is anticipated to catalyse the legalisation of medicinal cannabis in France, which is estimated to have a market value of €4 billion at maturity.
Commenting on the tender win, LGP Managing Director Fleta Solomon said LGP’s role as a primary supplier to the trial would provide the Company with a significant first mover advantage in the event medicinal cannabis is legalised in France following the trial.
“We are very proud of our Partnership’s success in the French national tender and see this tender win as strong evidence of LGP successfully implementing its export-led global sales strategy and demonstrating the benefits of Australian Good Manufacture Practices (GMP) quality manufacturing in global pharmaceutical markets,” Ms Solomon continued.
“We believe the trial will demonstrate the Partnership’s credibility and reliability to the French medical community, giving both companies a significant competitive advantage once medicinal cannabis is legalised in France.
“I’d like to congratulate both Intsel Chimos and LGP teams for their tireless efforts in developing a world-leading bid for the Tender.
“We trust this marks the beginning of a long and rewarding partnership as we look to grow and cement our reputation amongst French patients and prescribers as a world-class medicinal cannabis supplier,” she concluded.
Image credit: https://www.littlegreenpharma.com/
